West Pharmaceutical stock gains after insider sale and strong Q2 figures
Published on 09/11/2026 at 21:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
West Pharmaceutical Services Inc. stock (ISIN US9523901012) ended the September 10, 2026 session on the New York Stock Exchange at USD 344.25, up 2.17 percent from the prior close and near the upper end of its recent trading range, according to exchange data summarized by finance portals on September 11, 2026.
Insider sale highlights rally and valuation debate
A current catalyst for West Pharmaceutical stock is an insider transaction disclosed in a recent Securities and Exchange Commission filing and reported by Investing.com on September 11, 2026.
According to Investing.com on September 11, 2026, senior vice president and chief human resources officer Annette F. Favorite sold common shares worth about USD 2.77 million on September 8, 2026, at a weighted average price of USD 340.81 per share, after exercising stock options the same day at prices between USD 83.47 and USD 89.64 per share.
The same report from Investing.com notes that the insider sale occurred with West Pharmaceutical stock trading around USD 344.25 after a roughly 45 percent rise over the past six months, and that InvestingPro analysis currently views the shares as trading above estimated fair value.
Q2 2026 results beat expectations
In addition to the insider activity, the latest quarterly figures continue to underpin interest in West Pharmaceutical stock. As reported by Investing.com on September 11, 2026, West Pharmaceutical Services delivered stronger-than-expected second-quarter 2026 results, achieving adjusted earnings of USD 2.37 per share.
According to the same analysis by Investing.com, West Pharmaceutical generated revenue of USD 872.3 million in Q2 2026 and exceeded Wall Street forecasts on both the top line and adjusted earnings per share.
While the report does not specify the exact consensus figures, the combination of USD 872.3 million in revenue and USD 2.37 adjusted EPS for Q2 2026 is described as better than analysts had expected, indicating that West Pharmaceutical stock is currently supported by a tangible earnings beat rather than only valuation optimism.
Analyst consensus and guidance set the tone
The broader analyst picture for West Pharmaceutical stock remains constructive. A recent overview from MarketBeat updated on September 11, 2026 shows that the shares carry a consensus rating of Moderate Buy, based on one strong buy rating, 11 buy ratings and three hold ratings.
According to MarketBeat, the average 12-month price target for West Pharmaceutical Services stands at USD 373.85, with published targets ranging from USD 295.00 on the low end to USD 447.00 on the high end, implying about 8.4 percent upside from levels near USD 344 based on the portal's calculations.
In the same MarketBeat summary, West Pharmaceutical is shown with a trailing price-to-earnings ratio of 44.16 and a dividend yield of 0.26 percent, highlighting that investors are paying a premium valuation for the company’s growth and margin profile alongside a modest quarterly dividend.
MarketBeat also notes that West Pharmaceutical stock has been the subject of nine research reports in the past 90 days, which underlines sustained analyst attention on the company in the wake of its recent results and share price performance.
Recent price action and 52-week range
The recent trading pattern of West Pharmaceutical stock reflects those fundamentals and expectations. Data compiled by MarketBeat on September 11, 2026 shows that the shares traded between an intraday low of USD 331.99 and an intraday high of USD 344.92 in the latest session, with recent volume of 653,058 shares compared with an average volume of 429,230 shares.
According to the same MarketBeat quote page, West Pharmaceutical stock currently sits within a 52-week range of USD 223.83 to USD 386.00, meaning that the September 10, 2026 closing price of USD 344.25 on the New York Stock Exchange is roughly USD 120 above the 52-week low and about USD 42 below the 52-week high.
The MarketBeat overview also indicates that West Pharmaceutical’s market capitalization stands near USD 24.27 billion at current prices, underscoring its role as a sizeable healthcare supplier within the S&P 500 universe.
For investors, this combination of a share price closer to the top of its 52-week range, a valuation in the mid-40s on trailing earnings and an analyst target about 8.4 percent above the present level frames West Pharmaceutical stock as a growth name where expectations are already high.
Valuation views and medium-term drivers
The insider-sale coverage by Investing.com highlights concerns that West Pharmaceutical stock may be overvalued relative to certain fair-value models, even after delivering quarterly results that beat expectations.
In parallel, a valuation snapshot from Morningstar dated September 10, 2026 shows West Pharmaceutical trading at USD 344.25, up USD 7.31 or 2.17 percent on the day, and notes that the stock price stands at a premium relative to Morningstar’s assessed fair value.
According to Morningstar, West’s top-line growth is expected to be supported over time by secular trends in injectable drugs, particularly increasing use of biologic therapies, which underpin its packaging and delivery solutions.
That long-term demand backdrop helps explain why analysts continue to assign a Moderate Buy rating and an average target above the current price, while valuation-focused services caution that the shares trade at a premium, creating a tension that investors in West Pharmaceutical stock need to weigh when considering the recent rally and insider activity.
Stock level and investor takeaway
West Pharmaceutical stock closed at USD 344.25 on the New York Stock Exchange on September 10, 2026, with an intraday range between USD 331.99 and USD 344.92 and a one-day gain of 2.17 percent, based on recent quote data for the WST ticker in USD.
West Pharmaceutical stock facts
- Company: West Pharmaceutical Services, Inc.
- ISIN: US9523901012
- Ticker: WST
- Trading venue: New York Stock Exchange
- Price (as of September 10, 2026, 8:02 PM): 344.25 USD
- Market capitalization: 24.27 billion USD (as of September 11, 2026)
- Sector / Industry: Healthcare / Medical Supplies
- Index membership: S&P 500
